Non-Hodgkin's lymphoma: Clinical practice guidelines in oncology™ Journal Article
| Authors: | Zelenetz, A. D.; Advani, R. H.; Buadi, F.; Cabanillas, F.; Caligiuri, M. A.; Czuczman, M. S.; Damon, L. E.; Fayad, L.; Flinn, I. W.; Forero, A.; Glenn, M. J.; Gockerman, J. P.; Gordon, L. I.; Harris, N. L.; Hoppe, R. T.; Kaminski, M. S.; LaCasce, A. S.; Nademanee, A.; Porcu, P.; Press, O.; Prosnitz, L.; Smith, M. R.; Sotomayor, E. M.; Vose, J. M.; Yahalom, J. |
| Article Title: | Non-Hodgkin's lymphoma: Clinical practice guidelines in oncology™ |
| Abstract: | Non-Hodgkin's lymphomas (NHLs) may be classified on the basis of morphology, natural history, and immunophenotypic and molecular characteristics. These guidelines were developed for more common NHL histologic types, including chronic lymphocytic leukemia/small lymphocytic lymphoma, follicular lymphoma, and diffuse large B-cell lymphoma, and for less common entities with unique natural histories and therapies, such as marginal zone lymphoma, mantle cell lymphoma, and highly aggressive lymphoma subtypes, including Burkitt's, and lymphoblastic lymphomas and AIDS-related B-cell lymphomas. Certain components of the diagnosis and therapy of the various NHLs are similar. In all cases, an accurate pathologic diagnosis must first be made. © Journal of the National Comprehensive Cancer Network. |
| Keywords: | treatment response; fludarabine; prednisone; thalidomide; clinical trial; disease course; review; cisplatin; doxorubicin; disease classification; cytarabine; ibritumomab tiuxetan; methotrexate; rituximab; cancer staging; drug megadose; positron emission tomography; follow up; antineoplastic agent; cancer diagnosis; unindexed drug; cancer immunotherapy; mantle cell lymphoma; etoposide; clinical assessment; incidence; nccn clinical practice guidelines; alkylating agent; cyclophosphamide; dexamethasone; melphalan; vincristine; stem cell transplantation; cancer mortality; carmustine; ifosfamide; b cell lymphoma; nonhodgkin lymphoma; non-hodgkin's lymphoma; mitoxantrone; asparaginase; cancer relapse; immunophenotyping; immunomodulating agent; physical examination; diagnostic test; mesna; anthracycline; radioimmunotherapy; chronic lymphatic leukemia; tositumomab i 131; follicular lymphoma; marginal zone lymphoma; burkitt lymphoma; alemtuzumab; chlorambucil; pentostatin; lymphocytoma; thymocyte antibody; arabinoside; chronic lymphocytic leukemia; autotransplantation; lymphoblastoma; erythrocyte aplasia; stomach lymphoma; small lymphocytic lymphoma |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 4 |
| Issue: | 3 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2006-03-01 |
| Start Page: | 258 |
| End Page: | 310 |
| Language: | English |
| PROVIDER: | scopus |
| PUBMED: | 16507273 |
| DOI: | 10.6004/jnccn.2006.0025 |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 18" - "Export Date: 4 June 2012" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work